Purdue Pharma's OxyContin (oxycodone extended-release)
How one painkiller's marketing helped ignite the opioid epidemic
OxyContin, approved in 1995, is the single drug most closely associated with the US opioid crisis. Its marketing led to two criminal guilty pleas, thousands of lawsuits and one of the largest bankruptcy settlements in American history. This article examines the product itself: what Purdue claimed, what it knew, how it sold the drug, and what happened after it was reformulated.
Questions
What is OxyContin and why is it at the centre of the opioid crisis?
An extended-release oxycodone approved in 1995 — promoted as a long-term pain solution for common chronic conditions — whose aggressive marketing is linked to about 900,000 deaths since 1999 and more than $30 billion in Purdue revenues.
OxyContin is an extended-release formulation of oxycodone, a powerful opioid, intended to provide steady pain relief over 12 hours. It is a Schedule II controlled substance, the category with the highest potential for abuse among legally available drugs. Purdue's aggressive promotion from the late 1990s helped normalise long-term opioid prescribing for common chronic pain, not just cancer or end-of-life care. Lawsuits alleged Purdue downplayed OxyContin's addiction risk while encouraging doctors to prescribe it for chronic pain. The resulting crisis has been linked to about 900,000 deaths since 1999. OxyContin was also enormously profitable: Purdue reaped more than $30 billion from its sales over the years.
Q2What did Purdue falsely claim about OxyContin?
In its 2007 guilty plea Purdue admitted fraudulently marketing OxyContin as less addictive, less abusable and less likely to cause withdrawal than other painkillers — claims made without FDA approval or supporting research, and covering roughly 1995 to 2001.
In its 2007 guilty plea, Purdue admitted it had fraudulently marketed OxyContin by falsely claiming it was less addictive, less subject to abuse and less likely to cause withdrawal symptoms than other pain medications, with no medical research to support those claims and without FDA approval of them. The misconduct covered roughly 1995 to 2001. The US Attorney said Purdue "unleashed a highly abusable, addictive, and potentially dangerous drug on an unsuspecting and unknowing public". A central idea in the marketing was that the extended-release design made the drug harder to abuse. In practice, crushing or dissolving the tablets released the full dose at once, which made OxyContin attractive for misuse.
Q3What was the "12-hour problem"?
Internal documents showed Purdue knew the drug wore off before 12 hours in many patients — and reportedly told sales representatives to recommend higher doses rather than more frequent dosing, reinforcing dependence while raising overdose risk.
Purdue marketed OxyContin as providing 12 hours of relief, allowing twice-daily dosing, a key competitive advantage. A Los Angeles Times investigation, summarised by CBS News, reported that internal documents showed Purdue knew the drug wore off before 12 hours in many patients; in clinical trials many patients requested extra doses, and in one FDA analysis a third of cancer patients dropped out because the drug was ineffective. Rather than recommend more frequent dosing, which would have undermined the 12-hour claim, Purdue reportedly told sales representatives to recommend higher doses. When a dose wears off early, patients can experience withdrawal between doses, which may reinforce dependence, while higher doses raise overdose risk. The reporting reshaped public understanding of how the drug may have fuelled dependence, and prompted calls from members of Congress, including Senator Ed Markey, for an investigation into potentially deceptive claims.
Q4How did Purdue incentivise sales of higher doses?
A 1996 memo offered bonuses for 40mg sales and by 2014 more than half of long-term OxyContin patients were on doses the CDC later recommended avoiding — helped by McKinsey advice to "turbocharge" sales and focus on high-volume prescribers.
According to the LA Times reporting summarised by CBS, a 1996 internal memo offered bonus incentives stating "He who sells 40mg will win the battle". By 2014, more than half of long-term OxyContin patients were receiving doses the CDC later recommended doctors "avoid" or "carefully justify." Purdue also worked with consultancy McKinsey, which states said advised it to focus sales on "higher, more lucrative dosages", increase visits to high-volume prescribers, and design a plan to "turbocharge" OxyContin sales at the epidemic's peak. In 2021 McKinsey agreed to pay $573 million to nearly every state, without admitting wrongdoing, and committed never again to advise on opioid-related business.
Q5What happened in Purdue's 2007 criminal case?
Purdue pleaded to a felony; three executives to misdemeanours. Together they paid $634.5 million — about 90% of OxyContin profits during the offence period — with executives receiving three years' probation and 400 hours of community service. None went to prison.
The Purdue Frederick Company pleaded guilty to a felony charge of misbranding OxyContin with intent to defraud or mislead, and three executives, including the president, chief legal officer and former chief medical officer, pleaded guilty to misdemeanours. Together they paid $634.5 million. The US Attorney testified that the company's payment represented about 90% of its profit on OxyContin during the offence period, and that the executives received three years' probation and 400 hours of community service. They pleaded only as "responsible corporate officers," without admitting personal knowledge of the misbranding. OxyContin sales continued to grow afterwards, which critics later cited as evidence that the penalties had not changed the company's behaviour.
Q6What changed when OxyContin was reformulated in 2010?
Prescription opioid use stopped rising after the abuse-deterrent reformulation — but heroin overdose deaths began climbing the following month, particularly where heroin was already available, suggesting a near one-for-one substitution to more dangerous street drugs.
In August 2010 Purdue introduced an abuse-deterrent version of OxyContin that was harder to crush or dissolve. Research by economists at Notre Dame and elsewhere found that prescription opioid use stopped rising after the change, but heroin overdose deaths began climbing the following month, particularly in areas with greater pre-existing access to heroin and opioids. The authors described a one-for-one substitution of heroin deaths for opioid deaths. Their conclusion was that as long as cheap substitutes such as heroin, and later illicit fentanyl, are available, reformulating painkillers does little to reduce harm. Some commentators have disputed how much of the heroin surge the reformulation caused. But the research suggests that people who had become dependent on OxyContin shifted to more dangerous street drugs.
Q7What did Purdue admit in 2020 about OxyContin?
Three federal felonies: misleading regulators about anti-overprescribing efforts, paying kickbacks through an EHR company's opioid-alert software, and admitting in court to impeding the DEA's fight against the addiction crisis — against an $8.3 billion headline penalty mostly uncollectable in bankruptcy.
In October 2020 Purdue agreed to plead guilty to three federal felonies relating to OxyContin: defrauding the United States by misleading regulators about its efforts to restrict overprescribing, and violating anti-kickback laws by paying doctors to write more prescriptions. Prosecutors described how in 2015 Purdue negotiated with electronic health record company Practice Fusion to create software alerts designed to influence doctors to prescribe OxyContin when it was not medically necessary. Purdue also admitted impeding the DEA's efforts to combat the addiction crisis. The penalties totalled about $8.3 billion on paper, but because of the bankruptcy most was never expected to be collected. The Sackler family paid $225 million separately to resolve civil claims, without admitting wrongdoing.
Q8Who has been held responsible for OxyContin's harms?
The company (dissolved), three executives (misdemeanour pleas), McKinsey ($573M + $650M), and the Sackler family (up to $7B, no criminal charges) — while individual victims are expected to receive about $8,000–$16,000 each.
The company itself pleaded guilty twice and has been dissolved. Three executives pleaded guilty to misdemeanours in 2007. McKinsey paid $573 million to states and later $650 million to resolve a federal investigation of its consulting work for Purdue. The Sackler family agreed to contribute up to $7 billion under the 2025 bankruptcy plan, but none were criminally charged, and the family denied wrongdoing. The Supreme Court's 2024 ruling means anyone who did not opt into the settlement's releases can still sue individual family members. Individual victims were expected to receive about $8,000 to $16,000 each, which many consider small compared with the harm suffered.
Q9Is OxyContin still sold?
Purdue ceased to exist on May 1, 2026, when its assets passed to Knoa Pharma — an independent foundation focused on opioid-treatment medicines with no profit obligation. Oxycodone itself remains a widely used and legitimate medicine for severe pain.
Purdue Pharma ceased to exist when its bankruptcy plan took effect on May 1, 2026, and its assets passed to Knoa Pharma, a company owned by an independent foundation. Knoa is focused on providing opioid use disorder treatments and overdose reversal medicines, with no obligation to maximise profits, and operates under a strict injunction supervised by a monitor to ensure it sells its products safely. Oxycodone itself remains a legitimate and widely used medicine for severe pain, and extended-release opioids continue to be prescribed. The legacy of OxyContin is visible in today's tighter prescribing guidelines, prescription monitoring programmes and restrictions on opioid marketing, as well as the continuing illicit fentanyl crisis that followed.
Q10How much did the Sackler family benefit from OxyContin?
Purdue distributed more than $10 billion to or for the benefit of the Sacklers between 2008 and 2016, from a family fortune estimated at $13 billion, while OxyContin generated $1–3 billion in annual sales at its peak — the scale of withdrawals was central to creditor grievances in bankruptcy.
The Sackler family owned Purdue privately, and OxyContin was central to their wealth. One account says OxyContin generated $1 billion to $3 billion in annual sales from 2003 and that OxyContin sales made up most of a family fortune estimated at $13 billion, spread across about 20 family members. Between 2008 and 2016, Purdue distributed more than $10 billion to or for the benefit of the Sacklers. Family members have not been on Purdue's board or received payments since 2018, according to NPR. Lawsuits alleged that family members personally directed the marketing strategy that downplayed addiction risk; the family has denied wrongdoing. Under the 2025 settlement, the family will contribute up to $7 billion over 15 years and has agreed to stop putting its name on institutions in exchange for donations.
Q11What lessons does the OxyContin story hold?
OxyContin shows that a drug's marketing — not only its chemistry — can shape a public health crisis; that criminal penalties without prison time did not change behaviour; and that supply-side fixes like reformulation can backfire when dependence is already widespread.
OxyContin illustrates how a drug's marketing, not only its chemistry, can shape a public health crisis. Purdue's claims about lower addiction risk, its 12-hour dosing message, its push towards higher doses, and its use of consultants and electronic health record prompts to boost prescribing are now well documented through court admissions and litigation. It also shows the limits of enforcement: the 2007 penalties did not stop sales growth, the 2020 penalties went largely uncollected, and no individual owner faced criminal charges. Finally, the 2010 reformulation shows that supply-side fixes can have unintended consequences when dependence is already widespread. These lessons now inform the regulation of new drugs with abuse potential and the oversight of pharmaceutical promotion.